Glycolic Acid

Glycolic Acid

SCHEMBL376971

O=C([O-])CO.O=C([O-])CO.[Zn+2]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.50
OR51E2 Q9H255 1/20 0.44
CASP1 P29466 1/20 0.44
FFAR3 O14843 2/20 0.39
HDAC3 O15379 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
CA1 P00915 3/20 0.36
FAHD1 Q6P587 1/20 0.36
CA2 P00918 1/20 0.35
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycolic Acid SCHEMBL28715707 0.96 CA4 (0.47) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL8845857 0.92 CA4 (0.44) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL4522823 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL26512 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL1407330 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL15441504 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL21297631 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL991430 0.91
Glycolic Acid SCHEMBL1002389 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3
Glycolic Acid SCHEMBL1939806 0.91 CA4 (0.50) CA4OR51E2CASP1FFAR3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1074 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734970-A1 COMPOSITION COMPRISING HINOKITIOL AND ZINC SALT FOR USE IN THE TREATMENT OF HERPES LABIALIS AAA Investments B.V. (NL) 2026-05-06 EP claimed
EP-4688909-A1 POLYESTER ELASTOMERS FROM DI-CARBOXYLIC ACID OR TRI-CARBOXYLIC ACID, MONO-CARBOXYLIC ACID, AND POLYOL FOR COSMETIC AND PERSONAL CARE APPLICATIONS Momentive Performance Materials Inc. (US) 2026-02-11 EP claimed
EP-4605477-A2 METHODS AND ADDITIVES TO IMPROVE PERFORMANCE OF CARBON PARTICLES IN ELASTOMER COMPOSITES Monolith Materials, Inc. (US) 2025-08-27 EP claimed
EP-3801455-B1 MILD COMPOSITION FOR USE IN TOPICAL TREATMENT OF SKIN AND NAIL DISORDERS CAUSED BY VIRUS AND FUNGUS EVIDERM INST AB (SE) 2025-05-21 EP claimed
WO-2025003464-A1 COMPOSITION COMPRISING HINOKITIOL AND ZINC SALT FOR USE IN THE TREATMENT OF HERPES LABIALIS DUTCH RENEWABLE ENERGY B.V. (NL) 2025-01-02 WO claimed
US-20240382405-A1 POLYESTER ELASTOMERS FROM DI-CARBOXYLIC ACID OR TRI-CARBOXYLIC ACID, MONOCARBOXYLIC ACID, AND POLYOL FOR COSMETIC AND PERSONAL CARE APPLICATIONS MOMENTIVE PERFORMANCE MAT INC (US) 2024-11-21 US claimed
WO-2024206504-A1 POLYESTER ELASTOMERS FROM DI-CARBOXYLIC ACID OR TRI-CARBOXYLIC ACID, MONO-CARBOXYLIC ACID, AND POLYOL FOR COSMETIC AND PERSONAL CARE APPLICATIONS MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2024-10-03 WO claimed
EP-3721862-B1 ORAL CARE PREPARATIONS COMPRISING CHLORHEXIDINE AND ARGININE OR THEIR SALTS MEDA AB (SE) 2024-07-24 EP claimed
WO-2024086831-A2 METHODS AND ADDITIVES TO IMPROVE PERFORMANCE OF CARBON PARTICLES IN ELASTOMER COMPOSITES Monolith Materials, Inc. (US) 2024-04-25 WO claimed
US-20240097203-A1 ELECTROLYTE SOLUTION FOR AQUEOUS ZINC BATTERY AND AQUEOUS ZINC BATTERY KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2024-03-21 US claimed
US-5980477-A Genital lubricants with zinc salts as anti-viral additives Kelly, Patrick (US) 1999-11-09 US claimed
WO-1999003463-A1 GENITAL LUBRICANTS WITH ZINC TO REDUCE IRRITATION AND ALLERGIC REACTIONS KELLY PATRICK D (US) 1999-01-28 WO claimed
WO-1998056426-A1 CONTROLLED RELEASE MICROENCAPSULATED NGF FORMULATION GENENTECH, INC. (US) 1998-12-17 WO claimed
US-5798121-A ANTIDANDRUFF SHAMPOO L'OREAL (FR) 1998-08-25 US claimed
US-5785054-A Genital lubricant with zinc salt, labelled as anti-viral agent KELLY, PATRICK D. 1998-07-28 US claimed
US-5624675-A Genital lubricants containing zinc salts to reduce risk of HIV infection SNAPTRACK, INC 1997-04-29 US claimed
US-5599551-A Genital lubricants containing zinc as an anti-viral agent KELLY, PATRICK D. 1997-02-04 US claimed
US-5545673-A SPREADING MIXTURE CONTAINING WATER SOLUBLE ZINC SALT KELLY, PATRICK D. 1996-08-13 US claimed
US-5482053-A Condom lubricants containing zinc as an anti-viral agent KELLY, PATRICK D. 1996-01-09 US claimed
US-5208031-A Hermetic sealing a lubricant and viricide against herpes KELLY, PATRICK D. 1993-05-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382405-A1 POLYESTER ELASTOMERS FROM DI-CARBOXYLIC ACID OR TRI-CARBOXYLIC ACID, MONOCARBOXYLIC ACID, AND POLYOL FOR COSMETIC AND PERSONAL CARE APPLICATIONS CUTA, DDC, ACMSD CA4 892/4885OR51E2 2342/4885CASP1 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.